AlphaValue/Baader Europe Ups Novartis Price Target on 'Strong' Execution, 'Vigorous' Growth

02:28 AM EST, 12/08/2025 (MT Newswires) -- AlphaValue/Baader Europe raised its price target for Novartis (NOVN.SW), citing the pharmaceutical giant's "strong" execution and "vigorous" growth across its key segments. On Dec. 5, the research firm increased its price target by 7.68% to 124 francs, with an add rating. Analysts also lifted their earnings estimates, noting the drugmaker raised its outlook twice in 2025. "With 1/ presence in fast-growing high-margin areas, 2/ one of the strongest R&D engines in the industry, and 3/ the strategy of using bolt-on acquisitions over the years to avoid a patent cliff, Novartis should not find much trouble in achieving its mid-term targets," the note said. AlphaValue/Baader Europe added that Novartis' aim to grow sales at a 5% to 6% compound annual growth rate over the 2025 to 2030 period is "encouraging," given the key heart failure drug Entresto only lost exclusivity in 2025. Additionally, the research firm said Novartis' "healthy" balance sheet offers optionality to fuel expansion.